Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6828546 | 0.81 | ERN1 (0.47) | ALDH1A1GAANPC1RAB9ACYP3A4 | |
| SCHEMBL6828545 | 0.79 | TRIM24 (0.51) | ALDH1A1GAANPC1RAB9ACYP3A4 | |
| SCHEMBL11440351 | 0.78 | ALDH1A1 (0.58) | ALDH1A1GAANPC1RAB9ACYP3A4 | |
| SCHEMBL13369104 | 0.76 | CASP1 (0.42) | ALDH1A1GAACYP3A4HPGDMAPK1 | |
| SCHEMBL11786492 | 0.73 | GAA (0.50) | ALDH1A1GAANPC1RAB9AERN1 | |
| SCHEMBL10656799 | 0.73 | ALDH1A1 (0.49) | ALDH1A1GAANPC1RAB9ACYP3A4 | |
| SCHEMBL29427761 | 0.73 | ALDH1A1 (0.49) | ALDH1A1GAANPC1RAB9ACYP3A4 | |
| SCHEMBL13273692 | 0.72 | ALDH1A1 (0.45) | ALDH1A1GAANPC1RAB9ACYP3A4 | |
| SCHEMBL14283850 | 0.72 | CALM1 (0.53) | ALDH1A1RAB9AHPGDKDM4ESMN1; SMN2 | |
| SCHEMBL17286693 | 0.71 | ALDH1A1 (0.48) | ALDH1A1GAANPC1RAB9ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025036382-A1 | SULFONAMIDE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海复宏汉霖生物医药有限公司 | 2025-02-20 | — | — | WO | disclosed |
| EP-1824837-B1 | SUBSTITUTED N-SULFONYLAMINOBENZYL-2-PHENOXY ACETAMIDE COMPOUNDS | PFIZER (US) | 2008-08-13 | — | — | EP | disclosed |
| CN-101087771-A | Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds | PFIZER (US) | 2007-12-12 | — | — | CN | disclosed |
| EP-1824837-A1 | SUBSTITUTED N-SULFONYLAMINOBENZYL-2-PHENOXY ACETAMIDE COMPOUNDS | Pfizer, Inc. (US) | 2007-08-29 | — | — | EP | disclosed |
| US-7214824-B2 | Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists | PFIZER INC. (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214824-B2 | Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists | PFIZER INC. (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214824-B2 | Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists | PFIZER INC. (US) | 2007-05-08 | — | — | US | disclosed |
| WO-2006051378-A1 | SUBSTITUTED N-SULFONYLAMINOBENZYL-2-PHENOXY ACETAMIDE COMPOUNDS | PFIZER JAPAN INC. (JP) | 2006-05-18 | — | — | WO | disclosed |
| US-20060100460-A1 | Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists | PFIZER, INC. | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100460-A1 | Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists | CNR1, AVPR1A, OPRL1 | ALDH1A1 987/4885GAA 3884/4885NPC1 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.